MIAMI, March 31, 2014 (GLOBE NEWSWIRE) -- Tauriga Sciences Inc. (OTCQB:TAUG) or ("Tauriga" or "the Company"), a diversified life sciences company with key assets that include active license agreements, topical medicinal cannabis lotions, and a proprietary microbial fuel cell technology, today announced that it has fully repaid a convertible note ("the note") held by Group 10 Holdings, LLC ("Group 10 Holdings") for the principal amount of $157,500 USD. On September 30, 2013, Tauriga borrowed $157,500 USD from Group 10 while the Company was negotiating with Bacterial Robotics LLC ("Bacterial Robotics") to acquire synthetic biology pioneer Pilus Energy LLC ("Pilus Energy"). This capital infusion was crucial at that time, to provide the Company with the resources to execute the definitive merger agreement with Pilus Energy in late November 2013. The signing of that definitive agreement and the subsequent completion of the Pilus Energy acquisition on January 28, 2014 were unquestionably the catalysts that laid the foundation for future success. Including accrued interest and contractual buyout premiums, the note was fully repaid and retired for a cash payment of $225,487.36 USD. Therefore, there will be absolutely no share conversions owed to Group 10 Holdings in conjunction with this note and the corresponding debt has been removed from the Company's balance sheet.
As previously disclosed, the Company is working diligently to repay and retire the entirety of its remaining convertible debt and will update shareholders, once this important goal is accomplished.
Tauriga's CEO, Dr. Stella M.Sung expressed, "The Company continues to make excellent progress towards achieving the goal of eliminating its remaining convertible debt. In recent weeks the Company has significantly improved its balance sheet and I believe continues to make important progress in building shareholder value. The Company wishes to express its genuine appreciation to Group 10 Holdings and specifically Adam Wasserman for providing significant financial support last year, especially since that capital infusion was critical at that point in time. We believe this is an exciting time to be a shareholder of Tauriga Sciences and the foundation exists to build a successful and dynamic business."
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. On January 28, 2014 the Company completed its acquisition of Cincinnati, Ohio based Pilus Energy LLC ("Pilus Energy"), the developer of proprietary synthetic biology powered microbial fuel cell technology that creates electricity while consuming polluting molecules from wastewater. The Company's corporate websites can be found at ( www.tauriga.com ) and ( www.pilusenergy.com ).
NON SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Tauriga Sciences, Inc.: Dr. Stella M. Sung Chairman and Chief Executive Officer Tauriga Sciences, Inc. www.tauriga.com San Diego: + 1-858-353-5749 Montreal: + 1-514-840-3697 Email:
